Cost-effectiveness of using an extensively hydrolysed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in the US.

Cost-effectiveness of using an extensively hydrolysed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow's milk allergy in the US. Curr Med Res Opin. 2017 Nov 03;:1-24 Authors: Guest JF, Kobayashi RH, Mehta V, Neidich G Abstract OBJECTIVE: To estimate the cost-effectiveness of using an extensively hydrolysed casein formula containing the probiotic Lactobacillus rhamnosus GG, (eHCF+LGG; Nutramigen LGG) compared with eHCF alone, and amino acid formulae (AAF) in treating cow's milk allergy (CMA) in the US, from the perspective of third-party insurers and from parents. METHODS: A decision model was used to estimate the probability of cow's milk allergic infants developing tolerance to cow's milk by 18 months. The model also estimated the cost to insurers and parents (US dollars at 2016 prices) of managing infants over 18 months after starting one of the formulae, as well as the relative cost-effectiveness of each of the formulae. RESULTS: The probability of developing tolerance to cow's milk was higher among infants who were fed eHCF+LGG compared with those fed eHCF alone or an AAF. Infants who are initially fed with eHCF+LGG are expected to utilise fewer healthcare resources than those fed with one of the other formulae. Hence, the estimated total healthcare cost incurred by third-party insurers and parents of initially feeding infants with eHCF+LGG was less than that of feeding infants wit...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research